Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ensemble machine learning for predicting breast cancer recurrence and mortality using clinical and hemogram data.

NPJ breast cancer·2026
Same author

Aberrant O-glycosylation genes and miR-21-5p targets define a molecular signature of tumor aggressiveness in triple-negative breast cancer.

Glycobiology·2026
Same author

RNA-DNA Fusomer Fibers With Customizable Physicochemical, Mechanical, and Biological Properties for Next-Generation Therapeutics.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Liquid-based genomic profiling in high-risk localized prostate cancer.

Frontiers in urology·2026
Same author

Ganglioside GM3 in the Tumor Microenvironment: Mechanisms of Signaling Regulation and Strategies for Angiogenesis Inhibition.

Biomolecules·2026
Same author

MicroRNAs in penile cancer: challenges, opportunities, and translational perspectives.

Critical reviews in oncology/hematology·2026

Related Experiment Video

Updated: Mar 21, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

2.0K

Mitomycin C in pterygium treatment.

Thiago Gonçalves Dos Santos Martins1, Ana Luiza Fontes de Azevedo Costa2, Milton Ruiz Alves2

  • 1Federal University of São Paulo (UNIFESP), São Paulo 04023062, Brazil.

International Journal of Ophthalmology
|May 10, 2016
PubMed
Summary

Mitomycin C (MMC) can reduce pterygium recurrence after surgery. Higher MMC doses or longer use decrease recurrence but increase complication risks, requiring careful consideration of its use.

Keywords:
mitomycin Cpterygium surgeryrecurrence rate

More Related Videos

Author Spotlight: Enhancing Visual Outcomes in Cataract Surgery: A Novel Technique to Prevent Posterior Capsular Opacification Through IOL Rotation
04:59

Author Spotlight: Enhancing Visual Outcomes in Cataract Surgery: A Novel Technique to Prevent Posterior Capsular Opacification Through IOL Rotation

Published on: July 7, 2023

3.2K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.8K

Related Experiment Videos

Last Updated: Mar 21, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

2.0K
Author Spotlight: Enhancing Visual Outcomes in Cataract Surgery: A Novel Technique to Prevent Posterior Capsular Opacification Through IOL Rotation
04:59

Author Spotlight: Enhancing Visual Outcomes in Cataract Surgery: A Novel Technique to Prevent Posterior Capsular Opacification Through IOL Rotation

Published on: July 7, 2023

3.2K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.8K

Area of Science:

  • Ophthalmology
  • Surgical Oncology

Background:

  • Pterygium is a conjunctival lesion often linked to UV exposure.
  • Surgery is indicated for symptomatic pterygium unresponsive to conservative treatment.
  • Recurrence is a primary complication following pterygium excision.

Purpose of the Study:

  • To review the use of Mitomycin C (MMC) as an adjunct in pterygium surgery.
  • To determine optimal MMC dosage and administration duration.
  • To assess potential complications associated with MMC use.

Main Methods:

  • Literature review of studies investigating Mitomycin C in pterygium surgery.
  • Analysis of data on MMC dosage, duration, efficacy, and safety.
  • Evaluation of recurrence rates and complication profiles.

Main Results:

  • Mitomycin C acts as a fibroblast proliferation inhibitor.
  • Increased MMC exposure (dose or duration) correlates with reduced pterygium recurrence.
  • Higher MMC exposure is associated with an increased risk of complications.

Conclusions:

  • Mitomycin C is an effective adjunct for reducing pterygium recurrence.
  • Balancing efficacy and safety is crucial when determining MMC dosage and duration.
  • Further research may refine MMC protocols to minimize complications while maximizing efficacy.